Yang Fengwen, Wang Hucheng, Zou Jiahan, Li Xuemei, Jin Xinyao, Cao Yawen, Tian Jinhui, Ge Long, Lee Myeong Soo, Zhang Junhua
Evidence-Based Medicine Center.
Graduate School, Tianjin University of Traditional Chinese Medicine.
Medicine (Baltimore). 2018 Nov;97(47):e13052. doi: 10.1097/MD.0000000000013052.
An increasing number of network meta-analyses (NMAs) in traditional Chinese medicine (TCM) have been published recently, but the quality of them was lack of assessment. This study aims to evaluate the methodological and reporting quality of NMAs in TCM.
Six electronic databases, including PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), Embase, China National Knowledge Infrastructure (CNKI), Wanfang and Chinese Biomedical Literature Database (CBM) from inception to January 2018, were searched. NMAs of TCM were included. A measurement tool to assess the methodological quality of systematic reviews (AMSTAR) and the PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions (PRISMA-NMA) were used to assess the methodological and reporting quality of the included NMAs.
A total of 40 NMAs, including 2535 randomized controlled trials (RCTs), were included. They were published between December 2012 and November 2017. The median score and interquartile range of methodological and reporting quality was 7 (6-8) and 22 (19.1-27.1). Serious methodological flaws existed in the following aspects: the status of publication (22.5%), a list of studies provided (0%), assessment of publication bias (37.5%), and conflicts of interest (12.5%). Several items need to be improved in reporting, especially for Protocol and registration (2.5%), Data items (22.5%), Risk of bias across studies (Methods section) (37.5%), Results of individual studies (27.5%), Risk of bias across studies (Results section) (40%), Results of additional analyses (35%), and Funding (15%).
The methodological and reporting quality of NMAs in TCM is moderate. Identified shortcomings of published NMAs should be taken into consideration in further trainings of authors and editors of NMAs in TCM. Future researchers should be encouraged to apply PRISMA-NMA, and a recognized tool for the assessment of NMA methodology was wanted.
近年来,越来越多的中医药网络荟萃分析(NMA)被发表,但它们的质量缺乏评估。本研究旨在评价中医药NMA的方法学和报告质量。
检索6个电子数据库,包括自建库至2018年1月的PubMed、Cochrane对照试验中心注册库(CENTRAL)、Embase、中国知网(CNKI)、万方和中国生物医学文献数据库(CBM)。纳入中医药NMA。采用系统评价方法学质量评估工具(AMSTAR)和《卫生保健干预措施网络荟萃分析的系统评价报告PRISMA扩展声明》(PRISMA-NMA)评估纳入NMA的方法学和报告质量。
共纳入40项NMA,包括2535项随机对照试验(RCT)。它们发表于2012年12月至2017年11月之间。方法学和报告质量的中位数得分及四分位间距分别为7(6 - 8)和22(19.1 - 27.1)。在以下方面存在严重的方法学缺陷:发表状态(22.5%)、提供的研究列表(0%)、发表偏倚评估(37.5%)和利益冲突(12.5%)。报告方面有几个项目需要改进,特别是方案和注册(2.5%)、数据项(22.5%)、各研究间的偏倚风险(方法部分)(37.5%)、单个研究结果(27.5%)、各研究间的偏倚风险(结果部分)(40%)、额外分析结果(35%)和资金(15%)。
中医药NMA的方法学和报告质量中等。已发表NMA中发现的不足之处应在中医药NMA作者和编辑的进一步培训中予以考虑。应鼓励未来的研究者应用PRISMA-NMA,并且需要一个公认的NMA方法学评估工具。